Instructions for Testing

Important Note:

LeukoPrint® serves as an auxiliary diagnostic tool and should not be used as the sole basis for clinical decisions. All results require professional interpretation by professional clinicians.

Who should take this test?

The LeukoPrint® test is indicated for:

- Patients with failed karyotyping.
- Patients with suspected or diagnosed hematologic malignancies, such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), multiple myeloma (MM), acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL), etc.

Understanding your results:

- Tier.1 variation: Variants with strong clinical significance (Diagnostic, prognostic, and/or therapeutic).
- Tier.2 variation: Variants with some clinical significance (Diagnostic, prognostic, and/or therapeutic).
- Tier.3 variation: Clonal variants with no documented neoplastic disorder association.

Important reminders:

- Blood sample collection, transportation, storage, and non-standard processing may impact the performance of LeukoPrint®.
- LeukoPrint® only detected chromosomal aneuploidy abnormalities, copy number aberration (CNAs) ⩾ 1 Mb, and copy number neutral loss of heterozygosity (CN-LOHs) ⩾5 Mb in autosomal regions.
- The following chromosomal variants cannot be detected by LeukoPrint®: polyploidy, balanced translocation, Robertsonian translocation, inversion, and circular chromosomes, etc.
- Never rely on this test alone. The result must be confirmed by professionalqualified clinicians following clinical standardized procedures.

Questions?

Contact your doctor or our support team: info@seekincancer.com